18:44 , Nov 9, 2018 |  BC Week In Review  |  WIR Deals New Deals

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
18:33 , Nov 7, 2018 |  BC Extra  |  Financial News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
23:28 , Nov 2, 2018 |  BioCentury  |  Finance

Bye-bye, build-to-buy

As another Inception Sciences Inc. company secures an exit, Versant Ventures plans to move away from its build-to-buy model to focus on creating stand-alone companies with broader portfolios and investor syndicates. On Oct. 31, Ophthotech...
20:01 , Nov 2, 2018 |  BC Week In Review  |  Company News

Takeda proposes divestment of Shire GI candidate, announces loans

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it proposed to the European Commission a potential divestment of Crohn’s disease and ulcerative colitis candidate SHP647 once it completes its acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG). The move...
22:43 , Oct 26, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck...
19:29 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

CHMP backs Takhzyro, Dengue vaccine, biosimilar Herceptin

EMA’s CHMP on Oct. 19 recommended several approvals, including hereditary angioedema (HAE) mAb Takhzyro lanadelumab, dengue vaccine Dengvaxia and Herceptin trastuzumab biosimilar Ogivri. CHMP backed Takhzyro from Shire plc (LSE:SHP; NASDAQ:SHPG) to prevent recurrent attacks...
23:38 , Oct 19, 2018 |  BC Extra  |  Company News

CHMP backs Takhzyro, Dengue vaccine, biosimilar Herceptin

EMA’s CHMP recommended several approvals Friday, including hereditary angioedema (HAE) mAb Takhzyro lanadelumab, dengue vaccine Dengvaxia and Herceptin trastuzumab biosimilar Ogivri. CHMP backed Takhzyro from Shire plc (LSE:SHP; NASDAQ:SHPG) to prevent recurrent attacks of HAE....
19:37 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

FDA panel votes in favor of Shire’s constipation product

FDA’s Gastrointestinal Drugs Advisory committee voted unanimously in favor of approving an NDA from Shire plc (LSE:SHP; NASDAQ:SHPG) for prucalopride to treat chronic idiopathic constipation (CIC). Its PDUFA date is Dec. 21. The panel voted...
19:34 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

BioLineRx reports response, survival data for BL-8040, Keytruda combo in pancreatic cancer

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the Phase IIa COMBAT/KEYNOTE-202 trial showing that BL-8040 plus Keytruda pembrolizumab led to a disease control rate (DCR) of 34.5%, including one partial response and nine cases...
20:07 , Oct 11, 2018 |  BC Extra  |  Company News

Management tracks: Former Baxalta exec joins VisionGate; Carrick names Golumbeski chair

Cancer company VisionGate Inc. (Phoenix, Ariz.) hired John Glasspool as chief operating and strategy officer, a newly created position. He was EVP and head of corporate strategy and customer operations at Baxalta Inc., which Shire...